Seagen Inc. (SGEN) Bundle
A Brief History of Seagen Inc.
Seagen Inc. (SGEN), a biotechnology company focused on developing and commercializing innovative therapies for cancer, has experienced significant growth and transformation over the years. Founded in 1998, the company has pioneered the use of antibody-drug conjugates (ADCs) to enhance the effectiveness of cancer treatment.
Company Overview
As of 2024, Seagen's headquarters are located in Bothell, Washington. The company has established a robust pipeline of cancer therapies that leverage its proprietary ADC technology. Seagen markets several FDA-approved products, including ADCETRIS, PADCEV, TUKYSA, and TIVDAK.
Recent Financial Performance
For the nine months ended September 30, 2023, Seagen reported total revenues of $1.772 billion, a 24% increase from $1.434 billion in the same period of 2022. This growth was primarily driven by an increase in net product sales, which reached $1.583 billion, reflecting a 27% year-over-year increase.
| Financial Metric | 2023 (9 Months) | 2022 (9 Months) | % Change |
|---|---|---|---|
| Total Revenues | $1,772 million | $1,434 million | 24% |
| Net Product Sales | $1,583 million | $1,243 million | 27% |
| Net Loss | $(602) million | $(462) million | 30% |
| Research and Development Expenses | $1,205 million | $987 million | 22% |
| Cash, Cash Equivalents, and Investments | $1,237 million | $1,735 million | -29% |
Product Portfolio
Seagen's key products include:
- ADCETRIS (brentuximab vedotin)
- PADCEV (enfortumab vedotin-ejfv)
- TUKYSA (tucatinib)
- TIVDAK (tisotumab vedotin-tftv)
As of September 30, 2023, ADCETRIS generated $751 million in sales, marking a 25% increase from the prior year. PADCEV sales surged by 46% to $479 million, driven by its expanded use in first-line treatment settings.
Research and Development Focus
Seagen continues to invest heavily in research and development, with R&D expenses totaling $1.205 billion for the nine months ended September 30, 2023, an increase of 22% from $987 million in the same period of 2022. This investment supports the advancement of existing products and the development of new therapeutic candidates.
Recent Developments and Strategic Moves
In 2023, Seagen announced a merger agreement with Pfizer, which is expected to enhance its capabilities and market reach. The merger will likely impact Seagen's operational and financial strategies moving forward. The company has incurred approximately $40 million in acquisition-related expenses during the nine months ended September 30, 2023.
Market Position and Future Outlook
Seagen has established itself as a leader in the oncology space, particularly with its ADC technology. The company's strong financial performance and ongoing investments in R&D position it well for future growth. The anticipated completion of the merger with Pfizer could further bolster its market presence and operational efficiency.
| Product | 2023 Revenue (9 Months) | 2022 Revenue (9 Months) | % Change |
|---|---|---|---|
| ADCETRIS | $751 million | $601 million | 25% |
| PADCEV | $479 million | $329 million | 46% |
| TUKYSA | $289 million | $267 million | 8% |
| TIVDAK | $64 million | $45 million | 42% |
A Who Owns Seagen Inc. (SGEN)
Major Shareholders
As of September 30, 2023, the ownership structure of Seagen Inc. (SGEN) is characterized by significant shareholdings by key entities and individuals. Notably:
- The Baker Entities collectively beneficially owned approximately 24% of Seagen's common stock.
- Executive officers, directors, and holders of greater than five percent of outstanding common stock beneficially owned approximately 43% of the voting power.
Share Ownership Table
| Shareholder Type | Ownership Percentage | Details |
|---|---|---|
| Baker Entities | 24% | Significant influence over management and corporate affairs. |
| Executive Officers and Directors | 19% | Includes major decision-makers within the company. |
| Other Major Shareholders | Approximately 43% | Includes various institutional investors and funds. |
Impact of Ownership Structure
Due to the concentrated ownership, these shareholders can exert substantial influence over Seagen’s management decisions and corporate governance. This includes:
- Election of directors.
- Approval of significant corporate transactions.
- Potential delays in changes of control, such as mergers or acquisitions.
Recent Developments
Seagen is currently undergoing a merger with Pfizer Inc., which was announced in March 2023. The acquisition is valued at $43 billion, with Pfizer agreeing to pay $229 per share for Seagen. This merger is pending regulatory approvals and is expected to close in late 2023 or early 2024.
Financial Overview
As of September 30, 2023, Seagen reported:
- Total assets: $3.63 billion
- Total stockholders' equity: $2.55 billion
- Net loss for the nine months ended September 30, 2023: $602 million
Stock Performance
Seagen's stock performance has been influenced by its ongoing merger discussions and the financial results reported:
- Net product sales for the nine months ended September 30, 2023: $1.58 billion
- Net loss per share for the nine months: $3.21
Conclusion on Ownership Dynamics
This concentrated ownership structure, combined with the pending merger with Pfizer, positions Seagen for significant strategic shifts in the near future, which could impact shareholder value and corporate governance.
Seagen Inc. (SGEN) Mission Statement
Company Overview
Seagen Inc. (SGEN) is a biotechnology company focused on developing and commercializing innovative therapies for cancer treatment. The company is known for its proprietary antibody-drug conjugate (ADC) technology, which is designed to deliver targeted cancer therapies that minimize damage to healthy tissue.
Mission Statement
Seagen's mission is to improve the lives of patients with cancer by developing and delivering innovative therapies that target specific cancer cells. The company is committed to advancing science and technology to provide patients with effective treatment options.
Financial Performance as of September 30, 2023
As of the third quarter of 2023, Seagen reported significant financial metrics that reflect its growth trajectory and operational health:
| Metrics | Q3 2023 | Q3 2022 | Change (%) |
|---|---|---|---|
| Total Revenues | $648.7 million | $510.3 million | 27.1% |
| Net Product Sales | $570.7 million | $428.1 million | 33.3% |
| Research and Development Expenses | $449.0 million | $384.6 million | 16.8% |
| Selling, General and Administrative Expenses | $265.7 million | $210.4 million | 26.2% |
| Net Loss | $(215.8) million | $(190.8) million | 13.1% |
| Cash and Cash Equivalents | $1.2 billion | N/A | N/A |
Product Portfolio
Seagen's product portfolio includes:
- ADCETRIS® (brentuximab vedotin) - For certain CD30-expressing lymphomas.
- PADCEV® (enfortumab vedotin-ejfv) - For metastatic urothelial cancers.
- TUKYSA® (tucatinib) - For HER2-positive cancers.
- TIVDAK® (tisotumab vedotin-tftv) - For metastatic cervical cancers.
Strategic Goals
Seagen aims to:
- Expand its product pipeline to address additional cancer types.
- Enhance its ADC technology platform for improved efficacy and safety.
- Increase global market penetration through strategic collaborations and partnerships.
Recent Developments
In October 2023, Seagen received approval from the European Commission for its acquisition by Pfizer, which is expected to enhance its research capabilities and market reach.
Collaboration and License Agreements
Seagen's collaboration agreements are critical for its revenue generation:
| Collaboration Partner | Key Product | Revenue Contribution (Q3 2023) |
|---|---|---|
| Takeda | ADCETRIS | $63.6 million |
| Astellas | PADCEV | $199.5 million |
Future Outlook
Seagen anticipates continued growth in its product sales driven by expanding market access and ongoing clinical development efforts. The company is committed to investing in research and development to fuel its pipeline of innovative therapies.
How Seagen Inc. (SGEN) Works
Business Model
Seagen Inc. is a biotechnology company focused on developing and commercializing targeted therapies for cancer treatment. The company primarily markets four key products: ADCETRIS®, PADCEV®, TUKYSA®, and TIVDAK®.
Financial Performance
For the nine months ended September 30, 2023, Seagen reported total revenues of $1.77 billion, an increase from $1.43 billion in the same period of 2022.
| Revenue Component | 2023 (9 Months) | 2022 (9 Months) | % Change |
|---|---|---|---|
| Net Product Sales | $1,583.34 million | $1,242.89 million | 27% |
| Royalty Revenues | $144.93 million | $111.19 million | 30% |
| Collaboration and License Agreement Revenues | $43.93 million | $80.18 million | (45%) |
| Total Revenues | $1,772.20 million | $1,434.26 million | 24% |
Expenses
Total costs and expenses for the nine months ended September 30, 2023, were $2.41 billion, compared to $1.89 billion for the same period in 2022.
| Expense Component | 2023 (9 Months) | 2022 (9 Months) |
|---|---|---|
| Cost of Sales | $457.78 million | $301.85 million |
| Research and Development | $1,204.93 million | $986.52 million |
| Selling, General and Administrative | $746.06 million | $604.86 million |
| Total Costs and Expenses | $2,408.77 million | $1,893.23 million |
Net Loss
For the nine months ended September 30, 2023, Seagen incurred a net loss of $602.05 million, compared to a net loss of $462.14 million for the same period in 2022. The net loss per share for the period was $3.21 compared to $2.51 in the prior year.
Cash and Equity Position
As of September 30, 2023, Seagen had $1.2 billion in cash, cash equivalents, and investments, with total stockholders’ equity amounting to $2.55 billion.
| Financial Position | As of September 30, 2023 | As of December 31, 2022 |
|---|---|---|
| Total Assets | $3.63 billion | $3.67 billion |
| Total Liabilities | $1.08 billion | $0.87 billion |
| Stockholders' Equity | $2.55 billion | $2.80 billion |
Research and Development Focus
Seagen continues to invest heavily in R&D, with expenses reaching $1.20 billion for the nine months ended September 30, 2023. This represents a significant portion of their operational budget, reflecting ongoing clinical trials and product development efforts.
Collaboration Agreements
Seagen has several collaboration agreements that contribute to its revenue. For instance, it collaborates with Takeda for ADCETRIS and Astellas for PADCEV. These collaborations involve milestone payments and royalties based on sales performance.
Market Trends and Future Outlook
Seagen's growth is driven by the increasing demand for targeted cancer therapies and the expansion of its product portfolio. The company anticipates continued growth in its product sales supported by volume increases and upcoming product launches.
Recent Developments
As of October 2023, the European Commission approved the acquisition of Seagen by Pfizer, a transaction expected to close in late 2023 or early 2024, pending regulatory approvals.
Summary of Key Products
| Product | Indication | Sales (9 Months 2023) |
|---|---|---|
| ADCETRIS | CD30-expressing lymphomas | $750.99 million |
| PADCEV | Metastatic urothelial cancer | $479.45 million |
| TUKYSA | HER2-positive cancers | $288.65 million |
| TIVDAK | Metastatic cervical cancer | $64.25 million |
How Seagen Inc. (SGEN) Makes Money
Revenue Streams
Seagen Inc. generates revenue primarily through three main streams: net product sales, royalty revenues, and collaboration and license agreement revenues.
Net Product Sales
For the nine months ended September 30, 2023, Seagen reported net product sales of $1,583.3 million, reflecting a 27% increase from $1,242.9 million in the same period of 2022. The breakdown of net product sales is as follows:
| Product | Q3 2023 Sales ($ thousands) | Q3 2022 Sales ($ thousands) | % Change | YTD 2023 Sales ($ thousands) | YTD 2022 Sales ($ thousands) | % Change |
|---|---|---|---|---|---|---|
| ADCETRIS | 246,071 | 218,521 | 13% | 750,986 | 601,449 | 25% |
| PADCEV | 199,516 | 105,330 | 89% | 479,452 | 329,114 | 46% |
| TUKYSA | 102,071 | 87,771 | 16% | 288,651 | 267,235 | 8% |
| TIVDAK | 23,071 | 16,467 | 40% | 64,254 | 45,091 | 42% |
Royalty Revenues
Royalty revenues for the nine months ended September 30, 2023, amounted to $144.9 million, up from $111.2 million in the same period of 2022, representing a 30% increase. This growth is primarily attributed to higher royalties from sales of Polivy by Roche and increased sales of ADCETRIS by Takeda in their territories.
Collaboration and License Agreement Revenues
Collaboration and license agreement revenues decreased significantly to $43.9 million for the nine months ended September 30, 2023, compared to $80.2 million for the same period in 2022, reflecting a 45% decline. This decrease was mainly due to a prior period upfront license payment from Zai Lab and a milestone payment received from AbbVie in the previous year.
Costs and Expenses
Total costs and expenses for the nine months ended September 30, 2023, rose to $2,408.8 million, up from $1,893.2 million in the same period of 2022. Key components include:
| Expense Type | YTD 2023 ($ thousands) | YTD 2022 ($ thousands) | % Change |
|---|---|---|---|
| Cost of Sales | 457,783 | 301,848 | 52% |
| Research and Development | 1,204,930 | 986,518 | 22% |
| Selling, General and Administrative | 746,060 | 604,862 | 23% |
Net Loss
For the nine months ended September 30, 2023, Seagen reported a net loss of $602.1 million, compared to a net loss of $462.1 million for the same period in 2022. The increase in net loss is primarily due to rising operating expenses and the costs associated with ongoing research and development efforts.
Cash and Equity Position
As of September 30, 2023, Seagen had cash, cash equivalents, and investments totaling $1.2 billion, with total stockholders' equity amounting to $2.6 billion.
Future Prospects
Seagen's revenue growth is expected to be supported by continued sales volume growth across its product portfolio, including ADCETRIS, PADCEV, TUKYSA, and TIVDAK. The company anticipates further advancements in its pipeline and potential new collaborations to enhance its revenue streams in the future. However, the collaboration and license agreement revenues are subject to variability based on the progress of collaborations and market conditions.
Seagen Inc. (SGEN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support